By 2030, it is anticipated that the France Liver Cancer Therapeutics market will reach a value of $275.3 Mn from $80.6 Mn in 2022, growing at a CAGR of 16.6% during 2022-30. Liver Cancer Therapeutics in France is dominated by a few domestic pharmaceutical companies such as Sanofi, Servier, and Transgene. The Liver Cancer Therapeutics market in France is segmented into different types of cancer and different therapy types. Some of the major factors affecting the France Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
By 2030, it is anticipated that the France Liver Cancer Therapeutics market will reach a value of $275.3 Mn from $80.6 Mn in 2022, growing at a CAGR of 16.6% during 2022-30.
France is a developed country in Western Europe with various overseas territories and islands on other continents and in the Indian, Pacific, and Atlantic oceans. According to the most recent WHO data, 9,573 people died from liver cancer in France in 2020, accounting for 2 % of all fatalities. France ranks 61st in the world with an age-adjusted death rate of 6.66 per 100,000 population. TACE (transarterial chemoembolization) is an increasingly common surgery in France that delivers chemotherapy medications directly to the tumor via the hepatic artery. The chemotherapy medications are combined with a chemical that prevents blood supply to the tumor, allowing it to shrink. France's government spent 12.2 % of its GDP on healthcare in 2020.
Market Growth Drivers Analysis
Over the last few decades, the incidence of liver cancer in France has progressively increased, with more than 7,500 new cases detected each year. As a result, there is a high demand for liver cancer therapies. France has a skilled and productive workforce, as well as a rapidly changing demographic. The standard of infrastructure and public service facilities improves the efficiency of the country's business activities. These aspects could boost France's Liver Cancer Therapeutics market.
Market Restraints
Liver cancer therapies can be costly, and the high expense of therapy may prevent some patients from receiving them. This might potentially place a load on the healthcare system and impede market expansion. Drug corporations may be cautious to invest in innovative medical research if they believe the eventual product will be unprofitable due to a lack of patent protection or competition from generic drugs. These factors may deter new entrants into the France Liver Cancer Therapeutics market.
Key Players
January 2023: Servier and Aqemia announce the expansion of their new-molecule discovery cooperation on an unsolvable immuno-oncology therapeutic target. Aqemia has successfully used its proprietary quantum-physics-inspired artificial intelligence approach to find novel, patentable compounds that are experimentally active on a hitherto unsolved target in immuno-oncology.
In France, the regulation and reimbursement of liver cancer therapeutics are overseen by several entities, including the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) and the Haute Autorité de Santé (HAS). The reimbursement process for liver cancer therapeutics in France is largely determined by the national health insurance system, which is managed by the Caisse Nationale de l'Assurance Maladie (CNAM).
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Type (Revenue, USD Billion):
By Treatment (Revenue, USD Billion):
By Equipment (Revenue, USD Billion):
By Route of Administration (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
In France, the regulation of liver cancer therapeutics is overseen by several entities, including the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) and the Haute Autorité de Santé (HAS).
The reimbursement process for liver cancer therapeutics in France is largely determined by the national health insurance system, which is managed by the Caisse Nationale de l'Assurance Maladie (CNAM).
The Liver Cancer Therapeutics in France is dominated by a few domestic pharmaceutical companies such as Sanofi, Servier and Transgene.